Shopping Cart
Remove All
Your shopping cart is currently empty
Eblasakimab (ASLAN004) is a humanized monoclonal antibody targeting the IL-13 receptor alpha. By blocking IL-4 and IL-13 signaling through type 2 receptor inhibition, it can be used for studying atopic dermatitis.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $197 | - | In Stock | |
| 5 mg | $562 | - | In Stock | |
| 10 mg | $882 | - | In Stock | |
| 25 mg | $1,330 | - | In Stock | |
| 50 mg | $1,780 | - | In Stock |
| Description | Eblasakimab (ASLAN004) is a humanized monoclonal antibody targeting the IL-13 receptor alpha. By blocking IL-4 and IL-13 signaling through type 2 receptor inhibition, it can be used for studying atopic dermatitis. |
| In vitro | Eblasakimab is an interleukin (IL) -13 receptor alpha1 antagonist that blocks IL-4 and IL-13 signaling through type 2 receptors. [1] |
| Synonyms | CSL-334, CSL334, ASLAN004, ASLA N004 |
| Reactivity | Human |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Endotoxin | < 1.0 EU/mg |
| Conjucates | Unconjugated |
| Uniprot ID |
| Cas No. | 2445460-16-0 |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.